Exciting News from Carevive: Elevating Patient Experience in Oncology Research! Our Real-World Evidence (RWE) team, alongside our esteemed partners, recently showcased groundbreaking posters at prestigious conferences including ISPOR, ASCO, ASCO Quality, and ASH. These presentations, the culmination of collaborative efforts with leading academic institutions, underscore our commitment to advancing oncology research. We're proud to announce a significant milestone: the publication of three posters in collaboration with Takeda, shedding light on the patient experience in various hematologic malignancies. These publications mark our inaugural joint endeavors with industry, reinforcing our dedication to impactful partnerships. At Carevive, our mission to spearhead patient experience data in oncology remains unwavering. As we continue to build our 2024 collection, we invite you to explore our 2023 repository of publications and posters. https://lnkd.in/eceMxc3x Aaron Galaznik Keri Collette Mordecai Kramer Emelly Rusli Bruno Lempernesse Nadia Still DNP, RN April Boyd #carevive #digitaloncology #cancer #cancercare #oncology #patientreportedoutcomes #oncologydata #clinicalinnovation #drugcommercialization #RWD #RWE #smartdata
Carevive by Health Catalyst™’s Post
More Relevant Posts
-
Today, CureVac announced the financial results for the second quarter and first half of 2024 as well as business updates. Please find the press release here: https://lnkd.in/dVtyZv4Z We were especially pleased to share today that we’ve started of the dose expansion part B of our ongoing Phase 1 study evaluating our cancer vaccine candidate CVGBM in patients with resected glioblastoma. Preliminary[KR1] data from the dose-escalation Part A of the study will be presented in at ESMO - European Society for Medical Oncology Congress in September. For more information on the start of Part B of our Phase 1 study of CVGBM, please find a separate press release here: https://lnkd.in/dJncTHSX #mRNA #Oncology #Innovation
-
-
Today, OncWeekly officially joins the Formedics suite, focusing on the future of cancer care. HCPs now have seamless access to top-rated cancer trials, oncology research, and relevant news. Pharma and life science brands can align their messaging across deep content verticals covering over 35 cancer types. Read the full release for more info about this exciting launch! https://buff.ly/4bBXszS #Oncology #CancerCare #HealthcareInnovation
-
-
The DESTINY-Breast06 Trial is offering new hope for patients with hormone receptor-positive, HER2-low metastatic breast cancer. The study found that fam-trastuzumab deruxtecan (Enhertu) significantly improved progression-free survival (PFS) compared to standard chemotherapy. At VieCure, we recognize the importance of personalized treatment and the complexities that come with making data-driven decisions in oncology. Our platform helps community oncology practices stay up to date with the latest clinical research and trials, including findings like the DESTINY-Breast06 Trial. We enable healthcare teams to make guideline compliant and timely decisions that ensure patients receive the most effective, individualized treatments—helping ensure cancer patients live their best lives. #VieCure #Oncology https://lnkd.in/gV7AVAQ5
-
-
Love this graphic! Very creative and comprehensive! Premenopausal women newly diagnosed with ER+ breast cancer suddenly find themselves in the fast-lane of an information highway - and that may just be related to understanding the many specifics about the disease and how it is best treated. Those clinical concerns coexist with partnership, parenting, employment, insurance, and often - caregiving. Navigation coordinates these facets to help foster care of the whole person during her cancer experience. #carecoordination #oncologynursing #navigation #bestoutcomes
AONN+ is thrilled to share that our ER+ Premenopausal Breast Cancer Journey Pathway has been named the Pharma Choice Award – Variety Silver Winner by #PM360. This educational tool for navigators and patients was supported by TerSera Therapeutics and illustrates the clinical implications, challenges, and milestones premenopausal women with ER+ breast cancer face along their journeys. According to Jordan Henderson, Director of AONN+ Program Development, “we are thrilled to be honored with this award as it reflects the passion and hard work that went into developing this tool. We hope it benefits navigators who tirelessly educate and support their patients.” Read more about this tool and the PM360 award: https://bit.ly/3Ih9By8 #nursenavigator #patientnavigator
-
-
"Transforming HER2+ Breast Cancer Treatment: A Journey of Innovation" Since 1998, the landscape of HER2+ Breast Cancer treatment has dramatically evolved, showcasing remarkable advancements in therapeutic options. From the initial approval of Trastuzumab + chemo, we've witnessed a cascade of FDA approvals enhancing patient outcomes and quality of life. Key Milestones: 1998: Trastuzumab + Chemo 2006: Lapatinib + Capecitabine 2013: T-DM1 2019: Trastuzumab Deruxtecan 2020: Margetuximab + Chemo, Tucatinib + Capecitabine + Trastuzumab These advancements underscore the relentless pursuit of innovation in oncology, offering hope and new horizons for patients worldwide. #ASCO24 #Oncology #BreastCancerAwareness #CancerTreatment #HealthcareInnovation #FDAApproval #HER2Positive #MedicalAdvancements #PatientCare Follow our page for more industry updates: https://lnkd.in/de5zNWmK
-
-
At #AmplityHealth, our contract sales, medical, and communications experts have a front-row seat in advancing #immunotherapy and #precisionmedicine to combat cancer more effectively with our biopharma clients. Here are some key highlights from #ASCO24 Day 1: - Discussion of newly FDA-approved oncology agents - Presentation of 5 years of data from the CROWN study comparing lorlatinib and crizotinib in new patients with advanced ALK-positive non-small cell lung cancer - Analysis of research into whether circulating tumor DNA can help predict the effectiveness of neoadjuvant chemotherapy and evaluate the prognosis for those with early breast cancer View our full Day 1 summary and join our mailing list for updates: https://lnkd.in/euzvmUPG
-
-
The advances in healthcare today are moving at lightning speeds. Take some time to get to know how Caris Life Sciences is impacting this change! It just may be the change your loved one needs. Empower yourselves and impact your own healthcare through knowledge💙
Caris and collaborators from the biopharma industry and leading cancer centers, including those within the Caris Precision Oncology Alliance™ (POA), will collectively present 41 studies across 19 tumor types at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. “In collaboration with leading oncology experts in the POA, our clinicians and scientists leverage vast real-world evidence from over 632,000 lifetime clinical cases, including over 482,000 with matched molecular data and outcomes in Caris’ unique AI-driven platform, to unravel the complexities of cancer,” said Caris President David Spetzler Learn more: https://lnkd.in/gbFdygGP #ASCO24
-
-
Oncology accounts for 43% of current and planned clinical trials. Cancer is not even a top 10 global cause of death, according to the WHO. Only in mid/high-income countries did a form of cancer (Lung, Colon) represent a top-10 cause of death. Out of the 33,594 ongoing or upcoming phase I-III clinical trials with publicly available data, Oncology trials make up nearly 43%. https://lnkd.in/dnis9xWt
-
-
🌍 With global cancer cases projected to surge by 77% by 2050, staying at the forefront of oncology research and treatment is more important than ever. This month's edition of Veristat's Voyager newsletter dives deep into how our innovative approaches are accelerating positive outcomes in cancer trials. Find out how our efforts are decreasing the workload for sponsors and, more importantly, increasing hope for patients > https://lnkd.in/esPvwk6U #Veristat #Oncology #Cancer
Facing Global Oncology Clinical Development Hurdles
info.veristat.com
-
🔬 Excited for #ASCO24! 🎉 Mark your calendars for Tuesday, June 4, 2024, at 11am EST as we dive into the heart of cancer drug development. ASCO is THE conference for groundbreaking insights, and we're thrilled to bring you the latest from the frontline. Join us online as our experts decode the data readouts, revealing the strengths, weaknesses, and future directions of cancer treatment pipelines. Don't miss out on the biggest news shaping the oncology landscape today! Stay ahead of the curve with Endpoints.#Oncology #CancerResearch #EndpointsAtASCO #news #trends
Endpoints at #ASCO24
events.endpts.com
